10 May 2018 07:00
10th May, 2018
Byotrol Plc
("Byotrol" or the "Company")
APPROVAL RECEIVED FROM ALL U.S. STATES
FOR LONG-LASTING ANTI-MICROBIAL PRODUCT
FIRST US ORDER RECEIVED FOR ONWARD SALE ON AMAZON.COM
Byotrol plc, the specialist anti-microbial technology company, is pleased to announce that it has now completed the product registration process in the US for its 24-hour germ-kill surface sanitizer.
All 50 US states have now formally approved the product for sale, following receipt of approval from the US Environmental Protection Agency in June 2017.
The formulation has been under development at Byotrol for over 8 years and the Directors believe it offers unique performance characteristics, such as '24 hour surface protection against bacteria'. The Directors are not aware of any other EPA-approved product for US consumers that offers similar claims.
With the approvals in place, Byotrol is now able to sell in US retail, on-line and to institutional customers. We will be marketing our products under the name "Byotrol24"and will keep shareholders informed as we make further commercial progress.
We are also pleased to announce that we have already secured our first order for Byotrol24, for sale via a professional re-seller on Amazon.com. Whilst not yet meaningful in financial terms, this is a very important first step for us, not least as we have now completed the necessary registration processes for Amazon, the world's largest online shopping destination.
David Traynor, Chief Executive of Byotrol plc comments:
"We are now, finally, ready to go in the US. We are very excited to complete the various regulatory processes and can now move confidently on to commercialisation.
The order from the Amazon re-seller, whilst very small, is a key first step for us and we hope is the first in a series of positive announcements as we grow in the US."
Enquiries:
01925 742 000
David Traynor - Chief Executive, Byotrol plc
finnCap Ltd 020 7220 0500 (Nominated Adviser & Broker)
Geoff Nash/James Thompson - Corporate Finance
The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.
Notes to Editors:
Byotrol plc (BYOT.L), quoted on AIM, is a specialist developer of residual antimicrobial technologies, identifying, developing, formulating and commercialising cutting-edge antimicrobial solutions.
Our patented suite of technologies deliver powerful broad-spectrum efficacy with residual performance optimised against commonly occurring and industry-specific pathogens
Founded in 2005, the Company has developed the technology that creates easier, safer and cleaner lives
For more information, please go to www.byotrol.co.uk